On July 22, 2026, a new publication on carbetocin was released in the journal Clinical Therapeutics. The paper is titled "Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study." It reports results from the Compass PWS study, a randomized, placebo-controlled Phase 3 trial. Carbetocin remains classified as an unapproved research compound. This entry reflects the existence and title of the publication as indexed, without describing specific findings, outcomes, or safety conclusions from the study. Readers interested in the details of the trial's design or reported results should consult the original article directly through the journal or its indexed listing. For general background on carbetocin, including its research history and regulatory status, see the compound overview.
Carbetocin Phase 3 Compass PWS Study Published in Clinical Therapeutics
See the full carbetocin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42486751/